Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged generic · clear
Abbreviated New Drug Application (ANDA) litigation remains one of pharma’s most contested arenas. With market exclusivity and billions in annual sales on the line, each case influences competition, pricing, and the speed at which patients see…
As the relentless march of time continues, pharmaceutical executives find themselves facing the inevitability of patent expirations and the subsequent entry of generic or biosimilar competition. This reality underscores the imperative for continual…
Source: https://www.greyb.com/blog/drug-patents-expiring-2024/ The pharmaceutical industry is undergoing a important phase as numerous patents for key drugs are slated to expire in 2024. This impending expiration of patents signals a significant shift in…
In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This report series shines a spotlight on the intricate web of ANDA (Abbreviated New Drug Application) cases and…
When it comes to preparing an Abbreviated New Drug Application (ANDA), there are several common pitfalls that applicants often encounter. These pitfalls can significantly impact the approval process and delay the launch of a generic drug in the market.…
The Abbreviated New Drug Application (ANDA) process plays a vital role in the pharmaceutical industry, enabling generic drug manufacturers to bring affordable alternatives to market while respecting patent owner rights. Balancing the interests of patent…
Before the Supreme Court of the United States. On Writ of Certiorari from the United States Court of Appeals for the Fourth Circuit. Summary: A term styled "generic.com" is not necessarily generic and can be eligible for federal trademark…
